Emmaus Life Sciences, Inc.
EMMAOTCHealthcare● Active
$0.01
$-0.00(-4.95%)
Market Cap$673807
P/E Ratio—
52W High$0.0175
52W Low$0.008
Emmaus Life Sciences, Inc. (EMMA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EMMA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.05
Est. -$0.06 · +16.7%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
EMMA reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | -$0.06 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.06 | -$0.05 | +16.7% | $0.00B | $0.00B | +0.0% |
| ▼ Q1 FY2026 | Mar 30, 2026 | $0.01 | -$0.03 | -400.0% | $0.00B | $0.01B | -35.8% |
| — Q4 FY2025 | Nov 14, 2025 | — | -$0.03 | — | $0.00B | — | — |
| — Q3 FY2025 | Aug 14, 2025 | — | -$0.02 | — | $0.00B | — | — |
| — Q2 FY2025 | May 15, 2025 | — | -$0.04 | — | $0.00B | — | — |
| ▼ Q2 FY2025 | Apr 14, 2025 | $0.01 | -$0.03 | -373.7% | $0.00B | $0.01B | -45.1% |
| ▼ Q4 FY2024 | Nov 19, 2024 | $0.01 | -$0.01 | -200.0% | $0.01B | $0.01B | +9.6% |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
$0.00B
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
-$0.03
EPS Est.
$0.01
EPS Surpr.
-400.0%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 14, 2025Miss
EPS Actual
-$0.03
EPS Est.
$0.01
EPS Surpr.
-373.7%
Revenue
$0.00B
Q4 FY2024
Nov 19, 2024Miss
EPS Actual
-$0.01
EPS Est.
$0.01
EPS Surpr.
-200.0%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.01 | $0.01 | $0.01 | 1 |
| Q4 FY2029 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2029 | $0.01 | $0.01 | $0.01 | 1 |
| Q2 FY2029 | $0.01 | $0.01 | $0.01 | 1 |
| Q1 FY2029 | $0.03 | $0.03 | $0.03 | 1 |
| Q4 FY2028 | $-0.04 | $-0.04 | $-0.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +16.7% | $0.01 | $0.01 | +0.00% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -400.0% | $0.02 | $0.02 | -0.01% |
| — Q4 FY2025 | Nov 14, 2025 | — | $0.01 | $0.01 | +41.81% |
| — Q3 FY2025 | Aug 14, 2025 | — | $0.02 | $0.02 | +0.00% |
| — Q2 FY2025 | May 15, 2025 | — | $0.01 | $0.01 | +0.00% |
| ▼ Q2 FY2025 | Apr 14, 2025 | -373.7% | $0.02 | $0.02 | +0.00% |
| ▼ Q4 FY2024 | Nov 19, 2024 | -200.0% | $0.04 | $0.04 | +0.00% |
| — Q3 FY2024 | Sep 10, 2024 | — | $0.00 | $0.00 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 15, 2026
EPS Beat/Miss
+16.7%
Price Before
$0.01
Price After
$0.01
Q1 FY2026-0.01%
Report Date
Mar 30, 2026
EPS Beat/Miss
-400.0%
Price Before
$0.02
Price After
$0.02
Q4 FY2025+41.81%
Report Date
Nov 14, 2025
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q2 FY2025+0.00%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q2 FY2025+0.00%
Report Date
Apr 14, 2025
EPS Beat/Miss
-373.7%
Price Before
$0.02
Price After
$0.02
Q4 FY2024+0.00%
Report Date
Nov 19, 2024
EPS Beat/Miss
-200.0%
Price Before
$0.04
Price After
$0.04
Q3 FY2024+0.00%
Report Date
Sep 10, 2024
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Avg Beat Reaction+0.00%
Avg Miss Reaction-0.00%
Beat Rate1 / 8 quarters
Largest Move+41.81% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EMMA ends December
Emmaus Life Sciences, Inc. (EMMA) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.05 — beating the analyst consensus of $-0.06 by +16.7%. The next EMMA earnings date is expected around September 1, 2026.
Each quarter, investors track EMMA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EMMA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EMMA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EMMA earnings · 5 questionsEmmaus Life Sciences, Inc.'s next earnings report is expected around September 1, 2026. EMMA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EMMA historically reports after market close (AMC).
EMMA earnings datewhen is EMMA earningsEMMA next earnings datewhen does EMMA report earningsEMMA earnings calendar
▸ Source: FMP · Emmaus Life Sciences, Inc. SEC filings · US GAAP · Emmaus Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026